TY - JOUR
T1 - Peptide blocking ctla-4 and b7-1 interaction
AU - Podlesnykh, Stepan V.
AU - Abramova, Kristina E.
AU - Gordeeva, Anastasia
AU - Khlebnikov, Andrei I.
AU - Chapoval, Andrei I.
N1 - Funding Information:
This work was supported by the Russian Foundation for Basic Research (17-54-33003); Ministry of Science and Higher Education of the Russian Federation (FZMW-2020-0007); and by the Tomsk Polytechnic University Competitiveness Enhancement Program.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Discovery of the B7 family immune checkpoints such as CTLA-4 (CD152), PD-1 (CD279), as well as their ligands B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), and B7-DC (PD-L2, CD273), has opened new possibilities for cancer immunotherapy using monoclonal antibodies (mAb). The blockade of inhibitory receptors (CTLA-4 and PD-1) with specific mAb results in the activation of cancer patients’ T lymphocytes and tumor rejection. However, the use of mAb in clinics has several limitations including side effects and cost of treatment. The development of new low-molecular compounds that block immune checkpoints’ functional activity can help to overcome some of these limitations. In this paper, we describe a synthetic peptide (p344) containing 14 amino acids that specifically interact with CTLA-4 protein. A 3D computer model suggests that this peptide binds to the99MYPPPY104 loop of CTLA-4 protein and potentially blocks the contact of CTLA-4 receptor with B7-1 ligand. Experimental data confirm the peptide-specific interaction with CTLA-4 and its ability to partially block CTLA-4/B7-1 binding. The identified synthetic peptide can be used for the development of novel immune checkpoint inhibitors that can block CTLA-4 functional activity for cancer immunotherapy.
AB - Discovery of the B7 family immune checkpoints such as CTLA-4 (CD152), PD-1 (CD279), as well as their ligands B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), and B7-DC (PD-L2, CD273), has opened new possibilities for cancer immunotherapy using monoclonal antibodies (mAb). The blockade of inhibitory receptors (CTLA-4 and PD-1) with specific mAb results in the activation of cancer patients’ T lymphocytes and tumor rejection. However, the use of mAb in clinics has several limitations including side effects and cost of treatment. The development of new low-molecular compounds that block immune checkpoints’ functional activity can help to overcome some of these limitations. In this paper, we describe a synthetic peptide (p344) containing 14 amino acids that specifically interact with CTLA-4 protein. A 3D computer model suggests that this peptide binds to the99MYPPPY104 loop of CTLA-4 protein and potentially blocks the contact of CTLA-4 receptor with B7-1 ligand. Experimental data confirm the peptide-specific interaction with CTLA-4 and its ability to partially block CTLA-4/B7-1 binding. The identified synthetic peptide can be used for the development of novel immune checkpoint inhibitors that can block CTLA-4 functional activity for cancer immunotherapy.
KW - Cancer
KW - Immune checkpoints
KW - Immunotherapy
KW - Peptide microarray
KW - Peptides
UR - http://www.scopus.com/inward/record.url?scp=85099721241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099721241&partnerID=8YFLogxK
U2 - 10.3390/molecules26020253
DO - 10.3390/molecules26020253
M3 - Article
C2 - 33419027
AN - SCOPUS:85099721241
SN - 1420-3049
VL - 26
JO - Molecules
JF - Molecules
IS - 2
M1 - 253
ER -